[A25-70] Asciminib (chronic myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2025
Project no.:
A25-70
Commission:
Commission awarded on 28.05.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with ≥ 2 tyrosine kinase inhibitors
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-70
| Project no. | Title | Status |
|---|---|---|
| G22-32 | Asciminib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |